Is Irisin Anticancer Agent? †
Abstract
:1. Introduction
2. Conclusions
Author Contributions
Conflicts of Interest
References
- Pedersen, B.K.; Akerstrom, T.C.; Nielsen, A.R.; Fischer, C.P. Role of myokines in exercise and metabolism. J. Appl. Physiol. 2007, 103, 1093–1098. [Google Scholar] [CrossRef] [PubMed]
- Shao, L.; Li, H.; Chen, J.; Song, H.; Zhang, Y.; Wu, F.; Wang, W.; Zhang, W.; Wang, F.; Li, H.; et al. Irisin suppresses the migration, proliferation, and invasion of lung cancer cells via inhibition of epithelial-to-mesenchymal transition. Biochem. Biophys. Res. Commun. 2017, 485, 598–605. [Google Scholar] [CrossRef] [PubMed]
- Gaggini, M.; Cabiati, M.; Del Turco, S.; Navarra, T.; De Simone, P.; Filipponi, F.; Del Ry, S.; Gastaldelli, A.; Basta, G. Increased FNDC5/Irisin expression in human hepatocellular carcinoma. Peptides 2017, 88, 62–66. [Google Scholar] [CrossRef] [PubMed]
- So, W.Y.; Leung, P.S. Irisin ameliorates hepatic glucose/lipid metabolism and enhances cell survival in insulin-resistant human HepG2 cells through adenosine monophosphate-activated protein kinase signaling. Int. J. Biochem. Cell Biol. 2016, 78, 237–247. [Google Scholar] [CrossRef] [PubMed]
- Shi, G.; Tang, N.; Qiu, J.; Zhang, D.; Huang, F.; Cheng, Y.; Ding, K.; Li, W.; Zhang, P.; Tan, X. Irisin stimulates cell proliferation and invasion by targeting the PI3K/AKT pathway in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2017, 493, 585–591. [Google Scholar] [CrossRef] [PubMed]
- Provatopoulou, X.; Georgiou, G.P.; Kalogera, E.; Kalles, V.; Matiatou, M.A.; Papapanagiotou, L.; Sagkriotis, A.; Zografos, G.C.; Gounaris, A. Serum Irisin levels are lower in patients with breast cancer: Association with disease diagnosis and tumor characteristics. BMC Cancer 2015, 15, 898. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Zhang, X.; Li, H.; Liu, T.; Zhao, Q.; Huang, L.; Cao, Z.; He, L.; Hao, D. Serum Irisin associates with breast cancer to spinal metastasis. Medicine 2018, 97, e0524. [Google Scholar] [CrossRef] [PubMed]
- Gannon, N.; Garcia-Smith, R. Effects of the exercise-inducible myokine Irisin on malignant and non-malignant breast epithelial. Int. J. Cancer 2014, 136, E197–E202. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yıldırım, I. Is Irisin Anticancer Agent? Proceedings 2018, 2, 1561. https://doi.org/10.3390/proceedings2251561
Yıldırım I. Is Irisin Anticancer Agent? Proceedings. 2018; 2(25):1561. https://doi.org/10.3390/proceedings2251561
Chicago/Turabian StyleYıldırım, Işıl. 2018. "Is Irisin Anticancer Agent?" Proceedings 2, no. 25: 1561. https://doi.org/10.3390/proceedings2251561
APA StyleYıldırım, I. (2018). Is Irisin Anticancer Agent? Proceedings, 2(25), 1561. https://doi.org/10.3390/proceedings2251561